Mark Hollywood
Hoofd Techniek/Wetenschap/O&O bij ZYMEWORKS INC.
Profiel
Mark Hollywood is currently the EVP & Head-Technical & Manufacturing Operations at Zymeworks BC, Inc. and the EVP, Head-Technical & Manufacturing Operations at Zymeworks, Inc. Previously, he worked as the Director-Quality Assurance & Quality Control at CellCyte Genetics Corp.
and as the Vice President & Head-ZymoGenetics at Bristol Myers Squibb Co. He obtained his undergraduate degree from Western Illinois University.
Actieve functies van Mark Hollywood
| Bedrijven | Functie | Begin |
|---|---|---|
| ZYMEWORKS INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2019 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Hoofd Techniek/Wetenschap/O&O | 30-04-2019 |
Eerdere bekende functies van Mark Hollywood
| Bedrijven | Functie | Einde |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-01-2019 |
| CELLCYTE GENETICS CORPORATION | Corporate Officer/Principal | - |
Opleiding van Mark Hollywood
| Western Illinois University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ZYMEWORKS INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
CellCyte Genetics Corp.
 CellCyte Genetics Corp. Miscellaneous Commercial ServicesCommercial Services CellCyte Genetics Corp. engaged in the discovery and development of stem cell therapeutic products. It enabled therapeutic advancements to safely deliver stem cells through the patient's own circulatory or vascular system directly into a specific diseased, damaged or dying organ. The company was founded on March 9, 2004 and was headquartered in Freeland, WA. | Commercial Services |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
